UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000008999
Receipt No. R000010556
Scientific Title Dasatinib discontinuation for Chronic Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission.
Date of disclosure of the study information 2012/09/28
Last modified on 2012/09/28

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Dasatinib discontinuation for Chronic
Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission.
Acronym IMIDAS(Inter-Michinoku dasatinib study) 3rd Trial
Scientific Title Dasatinib discontinuation for Chronic
Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission.
Scientific Title:Acronym IMIDAS(Inter-Michinoku dasatinib study) 3rd Trial
Region
Japan

Condition
Condition chronic myeloid leukemia
Classification by specialty
Hematology and clinical oncology
Classification by malignancy Malignancy
Genomic information YES

Objectives
Narrative objectives1 The purpose of this study is molecular relapse free survival rate after discontinuation of dasatinib in patients with Chronic Myelogenous Leukemia-Chronic Phase who have maintained complete molecular remission for at least 1 year.
Basic objectives2 Safety
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2 Explanatory
Developmental phase Phase II

Assessment
Primary outcomes Molecular relapse free survival rate after discontinuation of dasatinib at 6 months.
Key secondary outcomes 1)Molecular relapse free survival rate after discontinuation of dasatinib at 12 months.
2)Evaluate potential prognostic factors for molecular relapse free survival.
i)We assessed LGL expansions,
ii)dose of dasatinib and time to CMR,
iii)total dose of dasatinib in last 12 months during CMR,
iv)methods and response of previous therapy,
v)previous interferon therapy,
vi)sex
vii) sokal risk group
3)Molecular remission rate after dasatinib re-challenge in cases of molecular relapse.

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Discontinuation of dasatinib in patients with Chronic Myelogenous Leukemia-Chronic Phase who have maintained complete molecular remission for at least 1 year.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
15 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1. Patients with Chronic Myelogenous Leukemia-Chronic Phase who have maintained complete molecular remission for at least 1 year.
2. ECOG performance status (PS) score 0-2
3. Adequate organ function (hepatic, renal and lung)
4. Signed written informed consent
Key exclusion criteria 1. Concurrent malignancy other than CML
2.Women who are pregnant or breastfeeding
3. A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy
4.Subjects with T315I, F317L and V299L BCR-ABL point mutations
5.Subjects with clonal evolution
Target sample size 50

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Yoji Ishida
Organization Iwate Medical Unversity,Internal Medicine
Division name hematology/oncology
Zip code
Address Uchimaru19-1, Morioka,Japan
TEL
Email

Public contact
Name of contact person
1st name
Middle name
Last name
Organization Iwate Medical Unversity,Internal Medicine
Division name hematology/oncology
Zip code
Address Uchimaru19-1, Morioka,Japan
TEL
Homepage URL
Email

Sponsor
Institute Epidemiological and Clinical Research Information Network(ECRIN)
Institute
Department

Funding Source
Organization Epidemiological and Clinical Research Information Network(ECRIN)
Organization
Division
Category of Funding Organization Non profit foundation
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2012 Year 09 Month 28 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2012 Year 07 Month 14 Day
Date of IRB
Anticipated trial start date
2012 Year 09 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2012 Year 09 Month 28 Day
Last modified on
2012 Year 09 Month 28 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010556

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.